Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clinical Trials Insight: 700024263

Trial Profile

Clinical Trials Insight: 700024263

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Feb 2008

At a glance

  • Drugs Nalbuphine (Primary)
  • Indications Musculoskeletal pain; Osteoarthritis; Pain
  • Focus Therapeutic Use
  • Sponsors Penwest Pharmaceuticals
  • Most Recent Events

    • 04 Feb 2008 Primary endpoint 'Sum of pain intensity difference' has not been met.
    • 04 Feb 2008 Primary endpoint not met; results reported in a Penwest media release.
    • 26 Oct 2007 Patient enrollment has been completed and preliminary results are expected in the first quarter of 2008.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top